PT - JOURNAL ARTICLE AU - Tamila Martynyuk AU - Kirill Zykov AU - Olga Antonova AU - Olga Arkhipova AU - Ekaterina Kobal AU - Valery Masenko AU - Sergey Nakonechnikov AU - Irina Chazova TI - Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension DP - 2012 Sep 01 TA - European Respiratory Journal PG - P407 VI - 40 IP - Suppl 56 4099 - http://erj.ersjournals.com/content/40/Suppl_56/P407.short 4100 - http://erj.ersjournals.com/content/40/Suppl_56/P407.full SO - Eur Respir J2012 Sep 01; 40 AB - Aim: to assess the influence of endothelin receptor antagonist Bosentan on cellular Immunity parameters in pts with idiopathic pulmonary arterial hypertension (IPAH).Methods: In the single-center comparative study we included 35 pts aged 35,2±9,6ys with IPAH confirmed by RHC (WHO Functional Class (FC) II-IV) without systemic inflammation signs. On top of stable therapy for at least 3 months Bosentan therapy was started 62,5 mg twice daily for 4 wks. At wk4 the patients were randomized 1:1 by the envelope method to have bosentan 125 or 250 mg/day. At baseline, at wk3 and wk12 visits the pts underwent the clinical and lab assessment (FC, 6-minute walking test (6-MWT), Echo, RHC,routine lab+CD-markers assessed by (fluorometry (Beckman Coulter FC 500).Results: All cellular immunity parameters of IPAH pts remained within normal limits.View this table:Conclusion: 12wk therapy with Bosentan changed CD-markers levels. The daily dose of 125mg resulted in the increase of B-lymphocytes levels and slight decrease of activated T lymphocytes, In patients treated with Bosentan 250 mg we found decreased numbers of activated B - and T-lymphocytes.